Illumina Announces RapidTrack Whole Genome Sequencing Service

Illumina, Inc. (NASDAQ: ILMN) today launched the RapidTrack Whole Genome Sequencing Service (RapidTrack WGS), a new offering in its FastTrack Sequencing Services operation that delivers a whole human genome in less than two weeks. The premium service offers the fastest sample-to-data turnaround time of any whole human genome sequencing service available today.

RapidTrack WGS utilizes Illumina’s new HiSeq 2500 sequencing system, which is capable of sequencing a complete human genome in one day. In combination with an accelerated sample preparation protocol and the Company’s new iSAAC genome alignment software, sample-to-data cycle time for a complete human genome is five days with the new service. To allow for queue time, RapidTrack WGS guarantees a turnaround of less than 14 days.

“Earlier this year, we previewed the rapid turn-around sequencing capabilities of the HiSeq 2500 system. Today, we are pleased to offer researchers access to the platform’s capabilities through RapidTrack WGS and our FastTrack Services,” said Jay Flatley, President and Chief Executive Officer of Illumina. “Additionally, we will shortly validate the HiSeq 2500 in our CLIA laboratory allowing fast response clinical sequencing. The processes and logistics established for our FastTrack research customers will ensure robust, high-quality results for the emerging clinical opportunity.”

By incorporating HiSeq 2500 into its Services operation, Illumina is deploying the capability to sequence a human genome in a day with unsurpassed data quality (>80% Q30 data) and the lowest sample input (3 μg) of any whole-genome sequencing service. RapidTrack WGS will deliver a full data set of all SNPs, indels, and structural variants in an industry-standard data format.

As a test of this novel capability, Illumina recently ran two test samples in conjunction with the Translational Genomics Research Institute (TGen). The samples were received on a Tuesday, and data for both samples were returned on the following Tuesday.

According to David W. Craig, Ph.D. and Matthew J. Huentelman Ph.D., co-directors of the Center for Rare Childhood Disorders at TGen, “We were pleased to see that the data quality was similar to what we have come to expect from the Illumina sequencers in our own laboratories. In fact, the scientists within our Center for Rare Childhood Disorders were able to identify mutations that are the likely genetic cause of one sequenced individual’s disorder, within 48 hours of receiving processed data from Illumina and less than 2 weeks from shipping DNA to the Company. We anticipate that this shortened timeline for sequencing and data processing, when accompanied by validation in a CLIA-certified laboratory, will substantially accelerate our ability to translate genomics research to the clinic in a timely manner.”

1 2 Next › Last »